MoonLake Immunotherapeutics Class A Ordinary Shares MLTX
i
Market datapartial · fetched 2026-11-12T01:24:09.776Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T23:12:50.135964402Z
FundamentalsAlpha Vantage · unavailable
MoonLake Immunotherapeutics Class A Ordinary Shares options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 16.46 | 127.3% | 23.1% | 11.67 | 131.1% | 16.8% |
| 25Δ | 15.56 | 109.4% | 16.8% | 12.12 | 127.4% | 14.2% |
| 30Δ | 14.98 | 101.0% | 13.0% | 12.51 | 118.6% | 11.9% |
| 35Δ | 14.66 | 98.4% | 11.2% | 12.91 | 109.9% | 9.5% |
| 40Δ | 14.34 | 95.8% | 9.4% | 13.17 | 100.6% | 7.9% |
| 45Δ | 14.02 | 93.2% | 7.6% | 13.39 | 91.1% | 6.6% |
| 50Δ | 13.76 | 93.3% | 6.7% | 13.61 | 81.7% | 5.2% |
| 55Δ | 13.51 | 93.5% | 5.7% | 13.83 | 72.2% | 3.8% |
| 60Δ | 13.26 | 93.7% | 4.8% | 14.10 | 68.9% | 2.8% |
| 65Δ | 13.00 | 93.9% | 3.9% | |||
| 70Δ | 12.74 | 91.9% | 3.2% | 17.90 | 245.6% | 5.9% |
| 75Δ | 12.48 | 89.9% | 2.5% | 18.74 | 238.6% | 4.5% |
| 80Δ | 12.22 | 87.9% | 1.8% | 22.16 | 292.9% | 4.0% |
20Δ
- Pseudo strike
- 16.46
- IV
- 127.3%
- B/E move
- 23.1%
- Pseudo strike
- 11.67
- IV
- 131.1%
- B/E move
- 16.8%
25Δ
- Pseudo strike
- 15.56
- IV
- 109.4%
- B/E move
- 16.8%
- Pseudo strike
- 12.12
- IV
- 127.4%
- B/E move
- 14.2%
30Δ
- Pseudo strike
- 14.98
- IV
- 101.0%
- B/E move
- 13.0%
- Pseudo strike
- 12.51
- IV
- 118.6%
- B/E move
- 11.9%
35Δ
- Pseudo strike
- 14.66
- IV
- 98.4%
- B/E move
- 11.2%
- Pseudo strike
- 12.91
- IV
- 109.9%
- B/E move
- 9.5%
40Δ
- Pseudo strike
- 14.34
- IV
- 95.8%
- B/E move
- 9.4%
- Pseudo strike
- 13.17
- IV
- 100.6%
- B/E move
- 7.9%
45Δ
- Pseudo strike
- 14.02
- IV
- 93.2%
- B/E move
- 7.6%
- Pseudo strike
- 13.39
- IV
- 91.1%
- B/E move
- 6.6%
50Δ
- Pseudo strike
- 13.76
- IV
- 93.3%
- B/E move
- 6.7%
- Pseudo strike
- 13.61
- IV
- 81.7%
- B/E move
- 5.2%
55Δ
- Pseudo strike
- 13.51
- IV
- 93.5%
- B/E move
- 5.7%
- Pseudo strike
- 13.83
- IV
- 72.2%
- B/E move
- 3.8%
60Δ
- Pseudo strike
- 13.26
- IV
- 93.7%
- B/E move
- 4.8%
- Pseudo strike
- 14.10
- IV
- 68.9%
- B/E move
- 2.8%
65Δ
- Pseudo strike
- 13.00
- IV
- 93.9%
- B/E move
- 3.9%
- Pseudo strike
- IV
- B/E move
70Δ
- Pseudo strike
- 12.74
- IV
- 91.9%
- B/E move
- 3.2%
- Pseudo strike
- 17.90
- IV
- 245.6%
- B/E move
- 5.9%
75Δ
- Pseudo strike
- 12.48
- IV
- 89.9%
- B/E move
- 2.5%
- Pseudo strike
- 18.74
- IV
- 238.6%
- B/E move
- 4.5%
80Δ
- Pseudo strike
- 12.22
- IV
- 87.9%
- B/E move
- 1.8%
- Pseudo strike
- 22.16
- IV
- 292.9%
- B/E move
- 4.0%
Options history
Table
| Date | IV (%) |
|---|---|
| 86.26% | |
| 86.79% | |
| 93.02% | |
| 91.77% | |
| 102.72% | |
| 95.34% | |
| 96.90% | |
| 100.77% | |
| 95.27% | |
| 100.04% |
Biotechnology
MLYS
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. The…
More →MNKD
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutics for endocrine and orphan lung diseases in the United…
More →MPLT
MapLight Therapeutics, Inc. is an innovative biotechnology company that is dedicated to developing groundbreaking therapies for complex neurological and psychiatric disorders.…
More →MRNA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases,…
More →MRVI
Maravai LifeSciences Holdings, Inc., a life sciences company, offers products to enable the development of drug therapies, diagnostics, novel vaccines, and to support human…
More →NAMS
NewAmsterdam Pharma Company N.V. is a forward-looking biotechnology firm focused on the development of innovative therapies for cardiometabolic diseases, leveraging its…
More →